MAT9001
Outclassing the omega-3 class.
MAT9001, our novel omega-3 fatty acid composition, has the potential to become the most impactful omega‑3 treatment for patients with elevated levels of triglycerides (TGs).
Lipid Nano-Crystal Platform
Improving the intracellular delivery of important therapeutics.
Our LNC platform enables safe, intracellular, and even orally-administered delivery of a broad range of drug therapies, including small molecules, drugs with blood level-limiting toxicities, nucleic acid polymers, proteins, peptides, vaccines, and gene editing technologies.
Based on our LNC technology, we have developed MAT2203 and MAT2501 – two potent treatments targeting life-threatening fungal and bacterial infections.
Matinas BioPharma to Webcast Conference Call on Q3 Results
News & More
Matinas BioPharma Awarded up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment of NTM Infections in Cystic Fibrosis Patients
Matinas BioPharma to Participate in Annual Piper Sandler Healthcare Conference
Contact us
